BIOSECURE Act Implementation Is Reshaping Peptide Supply Chains Two Years After Passage

BIOSECURE Act: Two Years of Real Impact

The BIOSECURE Act, enacted in 2024 to restrict US government-funded pharmaceutical manufacturing from specific Chinese entities deemed national security concerns, has had two years to generate observable effects on the peptide supply chain landscape. Those effects are now visible and accelerating, with the originally affected companies well into technology transfer processes and the broader Chinese pharmaceutical supply chain under heightened scrutiny from US pharmaceutical companies.

The restricted entities, most significantly WuXi AppTec and WuXi Biologics, were among the largest global peptide CDMO providers, with US peptide programs accounting for a substantial portion of their peptide contract manufacturing revenues. The restriction on US government-funded programs (which includes all programs receiving NIH, BARDA, DOD, or other federal research funding) has effectively required technology transfer for an estimated 23% of active US peptide programs that had engaged these entities for manufacturing services.

Understanding the actual implementation experience, what has worked, what has been challenging, and how the competitive landscape has shifted, is essential context for peptide companies still managing BIOSECURE compliance or making new manufacturing partnership decisions.

The Technology Transfer Experience

The technology transfer process, moving manufacturing from a restricted CDMO to a compliant provider, has been the central operational challenge for affected peptide programs in 2024-2026. The complexity and timeline of technology transfer varies significantly based on process complexity, the depth of process documentation at the originating facility, and the technical capabilities of the receiving facility.

Timeline realities: The average technology transfer from a WuXi AppTec peptide facility to a US or European CDMO has taken 14-18 months, including process knowledge transfer, receiving facility qualification, method transfer and validation, and first successful GMP campaign at the new location. Programs that began technology transfer processes immediately after BIOSECURE passage (mid-2024) have largely completed transitions; programs that delayed until closer to compliance deadlines are still mid-transfer in 2026.

Process documentation quality: The single largest determinant of technology transfer success and speed has been the quality of process documentation at the originating WuXi facility. Programs where WuXi had developed comprehensive batch records, process descriptions, and analytical method packages transferred more quickly and with fewer deviations than programs where process knowledge resided primarily in the experience of WuXi personnel rather than documentation.

Receiving facility selection: Companies that selected receiving facilities based primarily on cost and available capacity, rather than technical fit with the specific peptide process, experienced higher rates of transfer deviation and longer timelines to successful GMP manufacture. Companies that invested in careful technical due diligence of receiving facilities, including hands-on process run-through assessments, generally achieved smoother transfers.

Regulatory notification: FDA has provided clear guidance that technology transfers triggered by BIOSECURE compliance requirements should be reported in annual reports for existing approved products rather than through prior approval supplements, provided manufacturing changes do not affect product quality. This guidance significantly reduced the regulatory burden of BIOSECURE-driven transfers for commercial products.

Winners in the Supply Chain Transition

The supply chain displacement created by BIOSECURE restrictions has created substantial commercial opportunity for CDMOs and API manufacturers positioned as alternatives to the restricted Chinese entities.

Indian pharmaceutical manufacturers have been the largest non-US beneficiaries. Divi's Laboratories, which has established peptide API manufacturing capabilities over several years, has seen peptide API revenues grow 34% year-over-year as programs displaced from Chinese suppliers redirect demand. Piramal Pharma Solutions expanded its peptide contract manufacturing services significantly in 2025-2026, and Aurobindo Pharma's API division is in active expansion mode specifically to capture displaced peptide demand.

The Indian peptide manufacturing build-out is supported by both private investment and Indian government programs that position the country as an alternative pharmaceutical manufacturing hub to China. Quality standards at leading Indian peptide facilities have improved substantially, with several achieving FDA inspection records comparable to European standards.

South Korean CDMOs including Samsung Biologics (which expanded into peptide synthesis services in 2025) and smaller specialized Korean peptide manufacturers have similarly benefited. Korea is not subject to BIOSECURE restrictions and offers manufacturing cost structures significantly lower than US or European facilities, making Korean CDMOs natural alternatives for cost-sensitive programs.

US domestic CDMOs have benefited from both BIOSECURE-driven demand and from federal incentives designed to build domestic manufacturing capacity. The combination of commercial demand and government support has produced the capacity investment surge documented in recent CDMO market analyses.

European CDMOs, including Bachem (Switzerland), PolyPeptide Group (Sweden/Denmark), and Carbogen Amcis (Switzerland), have seen increased US program inquiries from companies seeking non-Chinese, non-government-restricted manufacturing alternatives with established quality track records.

Programs Still Mid-Transition

Not all BIOSECURE-affected programs completed technology transitions before compliance deadlines. A substantial number of programs, particularly those with complex synthesis processes, those that delayed initiation of technology transfer planning, and those that selected receiving facilities that proved inadequate, are still mid-transition in June 2026.

For these programs, the current situation varies significantly. Some are operating under FDA-granted compliance delay arrangements for specific program requirements; others are managing through supply agreements with non-restricted Chinese entities that are technically compliant but in geographic proximity to restricted entities; and others are using qualified imports of non-GMP material for research purposes while transferring GMP manufacturing to compliant facilities.

FDA has been pragmatic in managing BIOSECURE implementation for programs with active patient access needs, recognizing that abrupt supply disruptions would harm patients and that technology transfers cannot be instantaneously executed. The agency has worked with sponsors on transition timelines that balance compliance urgency with program continuity.

Broader Supply Chain Scrutiny

Beyond the specific BIOSECURE-restricted entities, the legislation has triggered broader scrutiny of Chinese pharmaceutical supply chain dependencies across the US peptide industry. Companies that were not directly affected by WuXi or BGI restrictions are evaluating other Chinese CDMO and API supplier relationships for potential regulatory risk in an environment where additional restrictions could be imposed.

This has produced a general de-risking trend toward supply chain geographic diversification that extends well beyond the specific BIOSECURE entities. Companies are establishing dual-source supply arrangements, qualifying US or European alternatives as secondary suppliers even where primary Chinese suppliers remain compliant, and incorporating supply chain risk into CDMO selection criteria in ways that were not standard practice before BIOSECURE.

The practical effect is a structural shift in how US pharmaceutical companies approach global supply chain design for peptide APIs and drug products, from a cost-optimization framework where lowest-cost reliable supply was the primary criterion, toward a risk-adjusted framework that explicitly values supply chain resilience and geopolitical durability alongside cost and technical quality.

Investment in Domestic Manufacturing

The BIOSECURE Act has been a significant catalyst for federal and private investment in US domestic peptide manufacturing capacity. Federal programs administered through BARDA, BioMADE, HHS, and the DOD have committed $320 million in manufacturing incentives targeting domestic peptide capacity expansion in H1 2026 alone.

These investments are building manufacturing infrastructure that will have lasting impact beyond BIOSECURE compliance. New domestic facilities that come online in 2027-2028 will address both the BIOSECURE-driven displacement demand and the underlying demand growth driven by the expanding peptide therapeutic pipeline.

For the peptide sector, the BIOSECURE Act has been a disruptive but ultimately clarifying force. The disruption of established supply chains is real and costly in the near term. The clarification, that geopolitically resilient supply chains require geographic diversification and domestic manufacturing capacity, will shape investment and operations decisions in the peptide industry for years beyond the immediate compliance requirements.